Exclusive: FDA probing death of Aduhelm patient as Biogen's Alzheimer's drug continues to stir controversy

John Carroll

Editor & Founder

Zachary Brennan

Senior Editor

The FDA tells Endpoints News today that it’s aware of the death of a patient taking Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab) and is “actively …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: FDA probing death of Aduhelm patient as Biogen's Alzheimer's drug continues to stir controversy

John Carroll

Editor & Founder

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ex­clu­sive: FDA prob­ing death of Aduhelm pa­tient as Bio­gen's Alzheimer's drug con­tin­ues to stir con­tro­ver­sy

Editor & Founder

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Exclusive: FDA probing death of Aduhelm patient as Biogen's Alzheimer's drug continues to stir controversy